Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.39 |
| ▸ | PPARA | Q07869 | 19/20 | 0.39 |
| ▸ | PPARD | Q03181 | 10/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6714350 | 0.97 | PPARG (0.41) | PPARGPPARAPPARD | |
| SCHEMBL6716265 | 0.95 | PPARG (0.38) | PPARGPPARAPPARD | |
| SCHEMBL6714343 | 0.95 | PPARG (0.38) | PPARGPPARAPPARD | |
| SCHEMBL6719798 | 0.95 | PPARG (0.39) | PPARGPPARAPPARD | |
| SCHEMBL6714592 | 0.95 | PPARA (0.36) | PPARGPPARAPPARD | |
| SCHEMBL6717548 | 0.94 | PPARG (0.38) | PPARGPPARAPPARD | |
| SCHEMBL6717293 | 0.94 | PPARG (0.39) | PPARGPPARAPPARD | |
| SCHEMBL6716029 | 0.94 | PPARG (0.43) | PPARGPPARAPPARD | |
| SCHEMBL6716185 | 0.94 | PPARG (0.41) | PPARGPPARAPPARD | |
| SCHEMBL6723980 | 0.93 | PPARG (0.46) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031764-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors(PPAR) | JEPPESEN LONE (DK) | 2001-10-18 | — | — | US | claimed |
| US-20010031762-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | JEPPESEN LONE (DK) | 2001-10-18 | — | — | US | claimed |
| US-20010031786-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | JEPPESEN LONE (DK) | 2001-10-18 | — | — | US | claimed |
| EP-1123269-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-08-16 | — | — | EP | claimed |
| WO-2000023417-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | claimed |
| US-20040229899-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | JEPPESEN LONE (DK) | 2004-11-18 | — | — | US | disclosed |
| US-6723731-B2 | 3-(4-(2-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLOXY)-ETHOXYL-PHENYL)-2 -ETHOXY-PROPIONIC ACID ETHYL ESTER AS ANTIDIABETIC AGENTS AND TO TREAT OBESITY | NOVO NORDISK A/S (DK) | 2004-04-20 | — | — | US | disclosed |
| US-6602901-B2 | Antidiabetic agents, obesity | NOVO NORDISK A/S (DK) | 2003-08-05 | — | — | US | disclosed |
| US-6407127-B2 | 3-(4-(2-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLOXY)-ETHOXYL-PHENYL)-2 -ETHOXY-PROPIONIC ACID ETHYL ESTER AS ANTIDIABETIC AGENTS AND TO TREAT OBESITY | NOVO NORDISK A/S (DK) | 2002-06-18 | — | — | US | disclosed |
| US-20010031764-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors(PPAR) | JEPPESEN LONE (DK) | 2001-10-18 | — | — | US | disclosed |
| US-20010031762-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | JEPPESEN LONE (DK) | 2001-10-18 | — | — | US | disclosed |
| US-20010031786-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | JEPPESEN LONE (DK) | 2001-10-18 | — | — | US | disclosed |
| EP-1123269-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-08-16 | — | — | EP | disclosed |
| US-6248781-B1 | ANTIDIABETIC AGENTS; DIETETICS | NOVO NORDISK A/S (DK) | 2001-06-19 | — | — | US | disclosed |
| WO-2000023417-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031762-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
| US-20010031786-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
| US-20010031764-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors(PPAR) | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
| US-20040229899-A1 | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.